title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
"AC Immune  ( ACIU )  Reports Q2 Loss, Misses Revenue Estimates",20230804T121506,https://www.zacks.com/stock/news/2132610/ac-immune-aciu-reports-q2-loss-misses-revenue-estimates,LGND,0.214937,Neutral,0.0
Stocks That Hit 52-Week Lows On Friday,20220506T160650,https://www.benzinga.com/markets/options/22/05/27050916/52-weeks-high-and-low-article,LGND,0.005467,Neutral,0.00032
Ligand  ( LGND )  Up 9% on FDA Nod for Molluscum Infection Gel,20240108T174700,https://www.zacks.com/stock/news/2207168/ligand-lgnd-up-9-on-fda-nod-for-molluscum-infection-gel,LGND,0.264658,Somewhat-Bullish,0.181149
"ImmunoGen  ( IMGN )  Q1 Earnings Beat, Elahere Uptake Encouraging",20230501T150000,https://www.zacks.com/stock/news/2087582/immunogen-imgn-q1-earnings-beat-elahere-uptake-encouraging,LGND,0.146692,Somewhat-Bullish,0.205863
"Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know - iShares Biotechnology ETF  ( NASDAQ:IBB ) , BondBloxx ETF Trust BondBloxx BB-Rated USD High Yield Corporate Bond ETF  ( ARCA:XBB ) ",20221101T200154,https://www.benzinga.com/general/biotech/22/11/29508633/provention-bios-second-try-apelliss-eye-disorder-drug-review-3-adcom-verdicts-and-more-novembers-,LGND,0.062761,Neutral,0.0
